Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis-Reference-Cited by-同舟云学术

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Published:2018-04-04 Issue:8 Volume:97 Page:1437-1443
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Hong Jung Yong,Yoon Dok Hyun,Suh Cheolwon,Kim Won Seog,Kim Seok Jin,Jo Jae-Cheol,Kim Jin Seok,Lee Won-Sik,Oh Sung Yong,Park Yong,Kim Sung-Yong,Lee Mark Hong,Lee Ho Sup,Do Young Rok

Funder

Asan Institute for Life Sciences

Eisai Korea Inc.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3317-6/fulltext.html

Reference18 articles.

1. Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin’s lymphoma. Oncogene 23:6524–6534. https://doi.org/10.1038/sj.onc.1207843

2. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391. https://doi.org/10.1016/S1470-2045(06)70664-7

3. Hong JY, Suh C, Kim WS (2016) Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Res 5. https://doi.org/10.12688/f1000research.8790.1

4. Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011:498–505. https://doi.org/10.1182/asheducation-2011.1.498

5. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540–1545. https://doi.org/10.1056/NEJM199512073332305

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach;European Journal of Haematology;2023-08-29

2. BR vs. R‑miniCHOP in unfit patients with B‑cell non‑Hodgkin lymphoma: A randomized, two‑center, cohort study;Oncology Letters;2023-08-23

3. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma;Annals of Hematology;2023-06-12

4. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors;Biomolecules;2023-01-05

5. Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone);Leukemia & Lymphoma;2022-02-02